January 13, 2020 Clinical Research/Diagn. M&A, Partnerships

QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer

Hilden, Germany and Germantown, Maryland, January 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics for non-small cell... Read more

January 6, 2020 Clinical Research/Diagn. M&A, Partnerships

Abcam announces successful acquisition of Expedeon’s Proteomics and Immunology business, enhancing its conjugation capability

Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSureTM Opportunity to combine Expedeon and Abcam’s technologies to create new products to support research and diagnostic development Cambridge, UK, -06 January 2020: Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon’s Proteomics... Read more

January 6, 2020 Clinical Research/Diagn. Life Science Tools PR/Corporate

Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President

Date: 01/06/2020 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this... Read more

December 23, 2019 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta’s investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At closing, Roche will pay an upfront of $750million in cash and $400million worth in equity Sarepta is eligible to receive up to $1.7billion in regulatory and sales milestones, plus royalties... Read more

December 17, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy

Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting... Read more

December 17, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche purchases shares in tender offer for Spark Therapeutics, Inc.

Roche intends to complete Spark acquisition today Basel, 17 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all... Read more

December 16, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc

All antitrust approvals required to close the transaction received. Basel, 16 December 2019  – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the Federal Trade Commission closed its investigation and granted unconditional clearance and termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976... Read more

December 16, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

Basel, 16 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of... Read more

December 10, 2019 Clinical Research/Diagn. Life Science Tools Mass Spectrometry Product Launch

Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging

Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of more than 100 pathologist-verified Maxpar® antibodies for use with Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System. This expanding collection now includes... Read more

December 9, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019

Basel, 09 December 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all... Read more